VerifyMe becomes OpenWorld on Nasdaq
The largest move on the list is VRME, up 10.3%, and the reason is structural rather than operational. VerifyMe's business combination closed and the company began trading on Nasdaq as OpenWorld, Inc. under the ticker OPNW, having changed its name effective the same day. OpenWorld works in real-world asset tokenization, building infrastructure to turn cash flows from operating businesses and physical assets into tokenized financial products for institutional investors. Founded in 2023, it says it has advised on projects representing over $66 billion in aggregate network value and supported more than 20 venture-backed companies, with backers including a16z, Multicoin, Dragonfly and Founders Fund. Matthew Shaw becomes Chairman and CEO; Russ McMeekin, previously a senior Honeywell executive, becomes Group President. Former VerifyMe CEO Adam Stedham framed the merger as the clearest path to shareholder value. The company also plans a dual listing on Figure OPEN, a blockchain trading platform, which it expects operational by November 2026. Maxim Group advised OpenWorld. Two 8-K filings accompany this, headline-only here, covering completion of the acquisition, change in control, unregistered equity sales, officer changes and a Reg FD disclosure.
Brazilian banks move together
Itaú and Bradesco both jumped, ITUB up 5.4% and BBD up 4.8%, and the only substantive item behind either is a Bradesco insider filing. The two chart items flag the size of the moves relative to their own volatility, ITUB roughly 1.5 times its 20-day ATR and BBD about 1.6 times, both on below-average volume, 0.7 and 0.6 times the 20-day average respectively. Neither chart page carried any explanation, and the ITUB link resolved to a consent screen with no article at all. The Bradesco item is a GuruFocus report that executive officer Marcello Di bought 57,160 shares on September 29, doubling his direct holding to 113,004 shares. GuruFocus notes 24 insider buys against 9 sells at Bradesco over the past year, a trailing P/E of 8.09 against an industry median of 11.58, and its own GF Value model calling the stock modestly overvalued. The Yahoo page shows BBD closing at $3.52, volume 30.4 million against a 29.4 million average, P/E 8.38, ex-dividend October 5 and next earnings estimated November 4. Note the GuruFocus piece quotes a $17.65 share price and a $35.22 billion market cap, which does not reconcile with the $3.52 close and $37.27 billion cap on the quote page, so treat its valuation arithmetic with care.
SoundHound in the Kia Sorento
SOUN is up 3.1% after announcing its voice and generative AI is now in the Kia Sorento in India, the first global deployment of the Kia AI Assistant with Real-Time Generative AI. A "Hey Kia" wake command handles climate, cabin lighting, windows and driving modes by conversation, and can pull answers from the vehicle's digital owner's manual on things like hybrid powertrain functions and seating. CEO Keyvan Mohajer supplied the quote. SoundHound says it holds more than 750 patents across automotive, financial services, healthcare, retail and telecoms. The same release ran twice on the list, from Investing.com UK and its news feed.
AMC down on a consumer promotion
AMC fell 2.6% on a day when its only news was a marketing launch, so the move isn't explained by the item. The company introduced an online booking platform for birthday parties offering up to 25% off private theatre rentals at roughly 300 US locations, bookable one to six weeks ahead, with food and beverage party packs and AMC-branded digital invitations through a partnership with Evite. Evite data cited in the release says AMC-hosted party attendance rose nearly 25% year on year, that close to 70% of movie theatre events on the platform are kid and teen birthdays, and that they are typically planned 25 days out for weekend slots. AMC runs about 850 theatres and 9,600 screens.
Iovance, new CMO plus a Wells Fargo target raise
IOVA is up 2.6% with two things behind it. Iovance named Noah Berkowitz, M.D., Ph.D., Chief Medical Officer effective Tuesday. He came from Arvinas, where as CMO he led the clinical strategy behind the first FDA approval of a targeted protein degradation therapy, and before that ran hematology at Bristol Myers Squibb, where his teams won approvals for the CAR T therapies Abecma and Breyanzi and oversaw programs contributing to Reblozyl sales above $2 billion a year. He received inducement options and RSUs covering up to 450,000 shares, options struck at $14.82, the grant-date close, vesting a third after one year then eight quarterly installments, with some RSUs tied to regulatory milestones. Separately, Wells Fargo's Yanan Zhu kept an Overweight rating and raised the target from $14 to $18. The GuruFocus write-up around that note puts Iovance's market cap near $6.63 billion, a GF Score of 37/100 with profitability ranked 1/10, and points out the company is unprofitable and cash-flow negative, so no GF Value is available and the historical median price-to-sales near 11.1 times is the reference point instead.
Generac, three conflicting reads on the same name
GNRC is down 2.5% and carries the busiest and most contradictory set of notes on the list. Citigroup kept a Neutral rating while cutting its target from $300 to $232, a 22.7% reduction, with the write-up describing a reassessment of growth prospects and risks in the current environment. Stifel's Stephen Gengaro, on the other hand, maintained Buy and nudged his target from $285 to $290. Both GuruFocus pieces lean the same way on valuation: a GF Value of $170.72 against prices of $208.44 and $212.22 in the two articles, making the stock 22% to 24% above that estimate, with a trailing P/E near 48 times versus a five-year median of 35.25. The GF Score is 87/100, strongest on profitability and growth at 8/10 each and weakest on valuation at 5/10. Insider selling totals $3,960,224 over three months, and of 15 gurus holding, 7 added and 9 trimmed. Against that, Matrix Asset Advisors' David Katz featured Generac in the firm's Q2 2026 Large Cap Value letter at a 6% allocation, citing backup power demand and product innovation while flagging supply chain constraints as a risk to production.
Take-Two consolidates its Xbox agreement
TTWO is up 2.3%. Take-Two disclosed a new long-term Xbox Publisher License Agreement with Microsoft, effective September 17, 2026, which supersedes and replaces all of its existing Xbox publisher agreements under one contract. It covers the right to develop, publish, manufacture, market, distribute and sell Xbox-compatible products across all Xbox devices. Microsoft pays the applicable wholesale price or agreed revenue share on digitally delivered products, and charges Take-Two fees and royalties on each physical unit manufactured. Microsoft retains approval rights over game concepts, final versions, packaging and marketing using its marks. Either side can terminate on material breach or insolvency, with sell-off rights for existing inventory afterward. The agreement will be filed as an exhibit to the 10-Q for the period ending September 30, 2026. GuruFocus puts GF Value near $229.58 and the GF Score at 80/100. The matching 8-K appears headline-only, as does a note on Wednesday option activity in PANW, TTWO and GLW.
Aflac, Japan Post trimming at the margin
AFL is down 1.7%, and the two GuruFocus items on it describe very small sales from a very large holder. Japan Post Holdings sold 12,200 shares at $114.55 on September 22 and 13,500 shares at $115.20 on September 23, leaving it with 50,493,590 shares, about 10.07% of Aflac and roughly 97% of its own reported equity portfolio, which consists of this single position. Both pieces read the sales as routine rebalancing given portfolio impact of about -0.02 to -0.03. On the stock itself: price $111.78, market cap $56.04 billion, P/E 11.98, ROE 16.69%, ROA 4.09%, interest coverage 24.91, Piotroski F-Score of 8, GF Score 77/100 with a weak growth rank of 2/10, and a GF Value of $129.16 putting shares about 13% below that estimate. The 14-day RSI reads 30.84. Across tracked gurus, 10 hold Aflac with 3 adding and 8 trimming. Two headline-only items sit alongside: a Form 4 dated September 30, and a GuruFocus piece whose headline asks whether AFL is undervalued on a DCF worth of $139.
Broadcom and the Anthropic lending disclosure
AVGO is down 1.1% despite the most consequential headline in the cluster: per an IPO prospectus, Broadcom will lend Anthropic up to $42 billion for infrastructure lease agreements, letting Anthropic lease Broadcom's chips. That ran across Reuters via Investing.com, GuruFocus and a market wire post, all headline-only, so the terms beyond the figure aren't available here. Other AVGO headlines are lower-grade: Netlist seeking an AI-memory import ban, Cathie Wood selling $110 million of AMD and buying Nvidia and Broadcom, net ETF buying of $143.0 million on Tuesday, and a TradingView chart note. A separate ETF flow headline shows technology as the most-bought sector on September 29.
Apple, a wall of headlines and a 1.1% gain
AAPL is up 1.1% and dominates the list by item count, though all of it is headline-only. On the sell side, Morgan Stanley cut its target to $355 from $360 while keeping Overweight, framing Apple as entering a major product cycle under new CEO John Ternus; Needham reiterated Hold citing competition risk from Meta; Bank of America flagged a risk to the stock in one headline and defended its buy rating against Muse disruption fears in another. On product: a smart-home push and new hub tied to an October 13 event, Apple Pay launching in India, iPhone 18 Pro sales up 12% in their China launch week per Counterpoint, and projections of 6 million foldable iPhone Duo units this year at $1,999. On the organization, several headlines point to Ternus targeting middle management with layoffs, with one tying the move to a memory chip crisis. The rest is ETF flow noise, roughly twenty separate items on funds buying or selling Apple alongside Nvidia.
SpaceX and the AI compute story
SPCX is up 1.1%. Needham reiterated Buy with a $250 target, pointing to announced AI compute deals reaching a combined $54 billion annualized revenue run rate and supporting a $100 billion ARR target. Macquarie is shown maintaining Outperform. ETFs bought $110.1 million of SPCX on Tuesday. Musk posts cover Starship Flight 14 and using Starship to place larger telescopes in orbit, and there are headlines on new Grok chatbot subscription pricing. All headline-only.
Oracle's data centre questions
ORCL is down 0.4% on a mixed headline set. Tencent is reported by the FT to have leased 100,000 chips from Oracle for about $7 billion to expand overseas AI capacity. Against that, Aterio flagged delay risk at Oracle's Wisconsin AI campus, and Oracle subsequently confirmed that flooding at Project Jupiter caused no major damage, with one headline noting a 5% dip. Other headlines reference a power bottleneck in the data centre buildout, congressional review of AI data centres covering Amazon, Google, Meta and Oracle, and Morgan Stanley seeing 50% upside without a Buy. Headline-only throughout.
Smaller movers and single-line items
The rest is thinner. COST is down 1.5% with nothing but a Frates insider sale of 801 shares, a Form 4, an ETF flow line and a geopolitical wire post on Iran and defence stocks that has no evident link to Costco. NFLX is down 1.0% against headlines that its co-CEO voiced growth concerns, saying the company is not growing as fast as he wants. VICR is down 0.6% even though the headlines are positive: it raised Q3 sequential growth guidance to over 30% on a new licensing deal, prompting a Needham target of $350, with several items describing a 10% surge, so the quote and the news are pointing opposite ways today. NBIS is down 0.6% with William Blair initiating at Outperform and a 12-year, 50 MW data centre deal with AIB. NVTS gained after early FTC clearance for the Claros acquisition, ASTS shipped three more BlueBird satellites, NTAP is up 0.4% on its Novus storage launch and a BofA target raise to $220, EXEL headlines note an all-time high at $59.73, RKLB has a 20-mission Synspective contract, and SNDK, TEVA, ALAB, MPC, TSM, PGY, PL, CMP, BBAI and SRFM carry one-line items with moves under a percent.
Brazilian banks lead the board
Itaú Unibanco was the biggest mover on the list, up 5.4% to $8.53, with Bradesco up 4.9% to $3.525 right alongside it. Neither of those items is news, they're Yahoo Finance quote pages, so there's no stated reason for the move in the material. What's there is context: ITUB traded 51.2 million shares against a 20.7 million average, put in a 13.7% month and 18.5% year to date, trades on a 10.5 trailing P/E with a $8.88 one-year target average, and JP Morgan maintained Overweight on 7 July while lifting its target from $9 to $10. Bradesco moved on 28.9 million shares, roughly its normal 29.8 million average, is up 8.5% on the month but only 4% year to date, sits at an 8.4 P/E with a 4.86% forward yield and a $4.30 average target. Santander Brasil was down 2.1% on the same screens, so this wasn't a clean sweep of Brazilian financials, but the two big private banks moving together this hard on no company-specific news is worth a look at the Brazil macro tape.
SoundHound lands Kia India
SoundHound was up 3.4% after announcing its voice and generative AI is now running in the Kia Sorento in India. This is the first global deployment of the Kia AI Assistant with Real-Time Generative AI, using a "Hey Kia" wake word to control climate, cabin lighting, windows and driving modes by speech, plus access to the digital owner's manual, point-of-interest navigation and news. CEO Keyvan Mohajer supplied the quote. No financial terms were disclosed. The company notes it holds over 750 patents. Two outlets carried the same press release, so treat it as one item, not two.
TMC adds an Exxon veteran to the board
The Metals Company was up 2.8% after naming Liam Mallon, a 35-year ExxonMobil executive, to its board and as chair of a new Sustainability and Innovation Committee. The timing is tied to the US government moving toward issuing deep-sea mining permits. TMC applied for US authorisation in 2025 to recover polymetallic nodules from the Clarion-Clipperton Zone containing nickel, copper, cobalt and manganese. It has no revenue, market cap of $1.67 billion, GF Score 37 out of 100 with profitability at 1 out of 10, and is down over 38% year to date, trading near its 52-week low of $3.40 against an $11.35 high. Insiders sold $2.4 million over twelve months with no purchases, while three gurus added.
AMC down, and mind which AMC
AMC was down 2.8%, and the two articles here are about different companies, so read them carefully. One covers AMC Networks (AMCX), which fell 4.1% on 29 September to $11.54, up 21.2% year to date, with GuruFocus calling it 24.9% overvalued against a $9.24 GF Value and flagging $0.2 million of insider selling with no buying. The other covers AMC Entertainment (AMC), which was the top communication services performer in September with a 27.03% monthly gain, market cap $2.73 billion, GF Score 52 with momentum at 9 but financial strength at 2, a distressed Altman Z-score of -0.87 and interest coverage of 0.49. Insiders there were net buyers of $345,000 over twelve months with no selling, and two of three gurus added. Today's move gives some of that September run back.
Generac, three angles and a gap
Generac was down 2.5%, which sits against a stack of constructive items. It rose 3.4% on 29 September to $212.22, within a 52-week range of $134.80 to $296.44. Stifel's Stephen Gengaro maintained Buy and nudged the target from $285 to $290 (the GuruFocus piece dates that action to October 2023, so the date is suspect). Matrix Asset Advisors disclosed a 6.0% allocation in its Q2 2026 large-cap value letter, with David Katz citing demand for backup power. TradeStation's TradingView note points to the 17 September gap higher on Amazon entering a long-term supply agreement that included warrants in Generac, with the stock holding in or above that gap, pushing above its 50-day average, the 8-day EMA crossing the 21-day and MACD rising. The counterweight in the same material: GF Score 87 but valuation 5 out of 10, a 48.9x trailing P/E versus a 35.4x five-year median, GuruFocus calling it roughly 24% overvalued, and $17.6 million of insider selling over twelve months with no buying.
Iovance after the guidance raise
Iovance was up 2.4%, an add-on to a much larger move. On 29 September the stock jumped over 30% after raising 2026 revenue guidance to $410-420 million against consensus near $403 million, close to 60% year-over-year growth. Goldman's Andrea Newkirk resumed coverage at Buy with a $15 target, citing Q2 Amtagvi sales of $91 million across 150 patients and arguing availability constraints are easing. Wells Fargo's Yanan Zhu kept Overweight and lifted the target from $14 to $18; HC Wainwright's Joseph Pantginis kept Buy and went from $9 to $20. Against that, the company is still unprofitable with a -91.17% operating margin, trades at 18.7x sales versus an 11.1x historical median, and carries a GF Score of 38 with profitability 1 out of 10, offset by financial strength of 7 and an Altman Z of 11.97.
Take-Two options volume
Take-Two was up 2.3% and showed up in a Nasdaq options-activity piece: 10,536 contracts traded, about 1.1 million underlying shares, or 41.8% of its 2.5 million average daily volume. The concentration was in the $240 strike call expiring 20 November, 858 contracts. Palo Alto and Corning appeared in the same note.
Aflac and Costco valuation notes
Aflac was down 1.6%, with a Form 4 filing headline and a DCF piece that lands on contradictory answers: earnings-based intrinsic value of $139.44 against a $113.66 price (18.5% margin of safety), but an FCF-based value of $54.13, which would make it heavily overvalued. GF Value sits at $129.16, GF Score 78, and the predictability rank is 0 out of 5, which the article itself flags as making the DCF unreliable. Insiders sold $222.5 million over the past year and eight of ten gurus trimmed. Costco was down 1.5%; its item has GF Value at $1,047.55 versus a $924.59 price, so 11.7% undervalued on that measure, a GF Score of 95 with growth and valuation both 10 out of 10 but momentum at 5, and $19.0 million of insider selling with no buying.
Apple, a large cluster with no single driver
Apple was up 1.2% and dominates the list by headline count, but all of it is headline-only. The recurring threads: John Ternus has taken over as CEO after Tim Cook and headlines point to a management shake-up targeting middle management and faster product cycles, with one headline mentioning layoffs amid a memory chip crisis. A smart-home hub launch is flagged for October 13. Counterpoint data has iPhone 18 Pro sales up 12% in China launch week. A foldable "iPhone Duo" at $1,999 is projected at 6 million units this year. Apple Pay launched in India. Bank of America is cited both defending its buy rating and flagging an AI threat from Meta's Muse. A long run of ETF flow headlines (SPY, QQQ, IVV, XLK and others buying or selling Apple) is routine index mechanics, not company news. Nothing here is read in full, so treat all of it as a pointer rather than substance.
The quieter names
The rest is mostly minor moves and headline-only flow. Navitas was down 1.1% on FTC clearance for its Claros acquisition and options activity; Broadcom also down 1.1% with headlines on Netlist seeking an AI-memory import ban and Cathie Wood buying. SpaceX was up 1.0% with a dense headline run on Starship Flight 14, a Needham Buy reiteration at $250 citing $54 billion of annualised AI compute deals, and Macquarie at Outperform. Netflix was down 1.0% despite a Deutsche Bank upgrade to Buy with the target cut from $100 to $95, plus exclusive WWE streaming rights in Japan from October 1. NetApp was up 0.4% on a heavy product-news day (Novus storage architecture, AI data engine updates, Supermicro partnership) and a BofA target raise to $220. Nebius was down 0.5% on a 12-year, 50 MW data centre deal with AIB. Oracle was down 0.3%, with headlines on reported delays at its Wisconsin AI campus and congressional scrutiny of AI data centres. Pagaya and Revolution Medicines both had routine insider sale Form 4s. Exelixis hit an all-time high of $59.73 while finishing down 0.4%. One incidental detail from the market wrap: Credo's COO Yat Tung Lam sold 100,000 shares at $206.29, about $20.63 million.
Macro backdrop in the source pages
Worth noting because it sits under several of these names: core PCE for August came in at +0.2% month-on-month, cooler than expected, and the Investing.com pages report October Fed hike bets fading on that plus dovish comments. The 10-year was at 5.29-5.30, up on the day, S&P 500 down 0.25%, Dow down 0.86%, Nasdaq up 0.24%.
Iovance jumps on raised 2026 guidance
IOVA is up 31.5%, the standout on the list, after the company filed an 8-K raising full-year 2026 revenue guidance to $410-420 million from a prior $350-370 million. That is roughly 15% higher at the midpoint, above the $402.8 million analyst consensus, and implies close to 60% annual growth. Management tied it to sustained and accelerating US demand for Amtagvi (lifileucel) and Proleukin. Interim President and CEO Frederick Vogt pointed to a record second quarter, $99.3 million of product revenue at a 56% gross margin, and said manufacturing schedules and patient demand give visibility into Q3 and Q4. The authorized treatment center network is approaching 100 with a year-end target of at least 110, and Q3 results are due in early November. The stock hit a 52-week high of $11.17 at the open after trading at $12.15 pre-market. Two supporting analyst items sit alongside this: Goldman Sachs' Andrea Newkirk resumed coverage days earlier with a Buy and a $15 target, citing $91 million of Amtagvi sales across 150 patients in Q2 and easing availability constraints, and HC Wainwright's Joseph Pantginis maintained Buy with the target raised from $9 to $20, though that GuruFocus write-up carries a confused internal date and is thin on new reasoning. Worth noting the GuruFocus pieces flag the valuation stretch, price-to-sales at 13.9 to 18.7 against an 11.1 historical median, with the company still unprofitable and cash-flow negative.
Sharp decliners with little explanation
BeyondSpring is down 31.0% on a headline-only 8-K covering entry into a material definitive agreement plus other events. The filing's contents aren't in the material here, so the driver of the move isn't established. VerifyMe is down 17.8% with only a Form 4 insider filing in the list, and that Investing.com item contains no detail on who traded or how much, so again no stated cause.
AMC down 6.4% after a strong month
AMC Entertainment fell 6.4%. The two full-read pieces are both backward-looking GuruFocus screens rather than news. One notes AMC closed September as the best-performing communication services stock, up 27.03% over the month, with a P/S of 0.34 against a 0.25 historical median, a GF Score of 52, a distressed Altman Z-score of -0.87, interest coverage of 0.49, negative TTM EPS of -1.06, and GF Value of $1.84 against roughly $3.06 trading. Insiders bought a net $345,000 over twelve months with no selling, and three gurus hold with two adding. Neither article gives a reason for today's decline. The second piece actually covers AMC Networks (AMCX), a different company, down 4.1% to $11.54, which GuruFocus calls 24.9% overvalued against a $9.24 GF Value.
Axsome down 4% with heavy put buying
AXSM fell 4.0% and the options tape is the story. Investing.com reports 92.7% of the day's volume was put-side, 1,922 puts against 151 calls, dominated by a fresh 1,200 by 600 ratio put spread expiring October 16: 600 long $185 puts and 1,200 long $170 puts. The $170 strike had prior open interest of just one contract, so this is new positioning rather than a roll. Three-month implied vol rose 2.37 points to 45.95% and 90/110 skew rose 0.30 points to 1.26. Context cited: the stock is down 23.82% over three months from a peak near $260, the ENGAGE Phase III readout for solriamfetol in binge eating disorder is due in Q4 2026, the CEO sold roughly $23.9 million of stock in June and July, and Q1 2026 missed on EPS ($1.26 loss versus $0.83 expected). Separately, Deutsche Bank's David Hoang kept a Buy but cut his target from $280 to $267, a 4.6% trim, with the note describing a cautious read on recent performance and market sentiment rather than anything company-specific. GuruFocus records $24.56 million of insider selling over three months.
Oracle up 3.9% on OpenAI revenue report
ORCL rose 3.9%, the largest gainer after IOVA among the names with real content. Investor's Business Daily attributes the move to an Axios report that OpenAI's annualized revenue run rate has reached close to $70 billion on enterprise sales, up more than 70% since the start of the year, which lifted Oracle and other OpenAI-linked names despite news that OpenAI scrapped a release plan for its next-generation model. The analyst debate is about returns rather than demand. Morgan Stanley's Sanjit Singh kept Equal Weight with a $210 target even while seeing about 50% upside, wanting evidence that the $90-95 billion annual capex reaffirmation converts into gross margin stability; the October 28 financial analyst day is flagged as the next checkpoint. Oracle reported $11.6 billion in quarterly cloud revenue, up 62%, with cloud infrastructure more than doubling to $7.4 billion and OCI up 121% year over year, against negative $5 billion free cash flow. Oppenheimer put Oracle among software vendors with AI businesses above $1 billion but noted buyers now want measurable returns. On the product side, Oracle Financial Services launched Nexus Case Flow and Nexus Reach, two AI tools for financial crime investigation, at the ACAMS conference in Las Vegas. Less helpfully, Oracle is one of four firms, with Amazon, Google and Meta, that House Judiciary member Jamie Raskin has asked to disclose confidentiality agreements with government officials over AI data center projects, an inquiry aimed at NDAs that keep communities in the dark about electricity, water and local finance implications. Three headline-only items round it out: an $18 billion Oracle AI project reportedly hitting a hurdle, a Form 4 insider filing, and a chart piece.
Mid-single-digit movers, headline only
Rocket Lab is down 3.4% and TMC down 3.1%, the latter alongside an 8-K and coverage of former ExxonMobil executive Liam Mallon joining the board ahead of a deep-sea mining push. Generac is up 3.4% with two conflicting-looking headlines, a GuruFocus piece on the 3.4% gain and a GF Score of 87, and a Jefferies price target cut on execution concerns. Mercury Systems is up 3.1%. All headline-only, so no detail behind them.
Apple down 2.7% on management shake-up headlines
AAPL fell 2.7% and carries by far the most headlines, though none were read in full. The recurring threads: new CEO John Ternus reportedly targeting middle management with layoffs and faster product development; a major smart-home push said to launch October 13; Apple Pay launching in India; iPhone 18 Pro sales up 12% in China launch week per Counterpoint; and Bank of America flagging an AI-related risk to the stock. Morgan Stanley reiterated with the target held at $360. A large share of the remaining Apple lines are routine daily ETF flow reports from GuruFocus rather than news.
SpaceX up 2.6% on AI compute thesis
SPCX rose 2.6%, with the headlines clustered around AI compute leasing rather than launch. Needham reiterated Buy at a $250 target, citing announced compute deals reaching a combined $54 billion annualized revenue run rate. TD Cowen initiated at Buy with a $200 target, expecting AI compute leasing to become the largest business by Q1 2027. BofA reiterated Buy after the Starship orbital test. Also in the list: a reported Starship engine failure that could affect NASA moon mission objectives, NASA giving Boeing Starliner a $359 million lifeline, and Beeline/VEON launching Starlink satellite-to-mobile in Kazakhstan.
Netflix upgraded, up 1.5%
NFLX gained 1.5% after Deutsche Bank upgraded to Buy from Hold while cutting the target to $95 from $100, the stated reasoning being global scale, an international production advantage and valuation at roughly 18x estimated earnings. Separately, Netflix secured exclusive WWE streaming rights in Japan from October 1. Headline-only.
The quieter rest
NetApp is up 2.3% on a dense run of product headlines from its INSIGHT conference: the Novus storage architecture for AI workloads, AI data engine updates, an expanded Commvault tie, a Supermicro partnership, a European data sovereignty service, and a BofA target raise to $220. Nebius up 2.4% on a 50 MW data center deal with AIB. Astera Labs up 1.9%, Broadcom up 1.6%, TSMC up 0.9% on 2nm expansion chatter, SanDisk up 1.0%, Marathon Petroleum up 0.7%, Constellation Software up 0.6%. Pagaya is up 2.2% against three separate insider sales, president Sanjiv Das at $243,672, CFO Jonathan Dobres at $10,053, and CAO Cory Vieira at $36,976. Butterfly Network was initiated at Outperform by Evercore ISI. Amphenol, Costco, Aflac, Navitas and the remainder are essentially flat with only screening or ETF-flow items behind them.
Iovance up 32% on a big guidance raise
IOVA is the day's outlier, up 32.1%, and the reason is concrete. In a Form 8-K filed Tuesday morning, Iovance lifted full-year 2026 total revenue guidance to $410-$420 million from $350-$370 million, roughly 15% higher at the midpoint, above the analyst consensus of about $402.8 million and implying close to 60% annual growth. Management attributed it to sustained and accelerating demand for Amtagvi (lifileucel) and Proleukin across US treatment centres. Interim President and CEO Frederick Vogt pointed to the record second quarter, $99.3 million of product revenue at a 56% gross margin, as giving visibility into the back half, and the update closes out the formal review flagged when Q2 was reported in August. The authorised treatment centre network is approaching 100 with a year-end target of at least 110. The stock hit a 52-week high of $11.17 at the open and closed at $14.45, up 31.48% on the day, on volume of roughly 75.8 million shares against a 16.6 million average. Q3 results are due 5 November.
The analyst side of the Iovance move
Two separate notes sit behind and alongside the guidance. Goldman Sachs resumed coverage days earlier, analyst Andrea Newkirk with a Buy and a $15 target, citing Amtagvi's Q2 of $91 million in sales across 150 patients, easing availability constraints, and a proprietary physician survey showing strong demand for the drug as second-line melanoma treatment. Separately, HC Wainwright's Joseph Pantginis maintained Buy and raised his target from $9 to $20, though note that GuruFocus item is internally inconsistent on dates, it is tagged 29 September 2026 but describes the action as taken on 24 October 2023. The GuruFocus coverage also flags the other side: Iovance is still unprofitable, with TTM profit margin around -89%, negative free cash flow, and a price-to-sales ratio well above its historical median of about 11. One of the five IOVA items also headlines the move as +19.2% on volume 0.3x average, which contradicts the closing data on the same page showing +31.48% on 4.6x average volume, so treat that line as unreliable.
BeyondSpring and VerifyMe both down hard
BYSI is down 31.0% and the only item is an 8-K covering entry into a material definitive agreement plus other events. Headline only, so the contents of that agreement aren't described here, and it's the obvious thing to pull the filing on. VRME is down 14.3% against a Form 4 insider filing and an 8-K exhibit filing; the Form 4 article carried no body text at all, so there's no detail on who traded or how much.
AMC down 7.1% after a strong month
AMC fell 7.1%. The GuruFocus piece is backward-looking rather than an explanation of today: it notes AMC was the best performer in communication services over the past month, up 27.03%, with net insider buying of $345,000 over twelve months and no insider selling, and three gurus holding with two adding. It also sets out the weak side, an Altman Z-score of -0.87, interest coverage of 0.49, TTM EPS of -1.06, and a GF Value of $1.84 against a price around $3.06. A TradingView post from a retail author describes a daily double-bottom breakout with support at $2.70-$2.80. Nothing in either item accounts for today's decline.
Oracle up 4% with genuinely mixed news
ORCL rose 4.0% to $137.91 on 42.6 million shares. The likely driver is the OpenAI read-across: Investor's Business Daily, citing Axios, reports OpenAI's annualised revenue run rate has grown more than 70% since the start of the year to close to $70 billion on enterprise sales strength, which lifted Oracle and other OpenAI-linked names even as OpenAI scrapped a release plan for its next model. Against that, a Reuters-sourced GuruFocus piece describes Oracle invoking force majeure over Project Jupiter, the 1,400-acre STACK Infrastructure data centre in New Mexico built for OpenAI, which may slip about a year on power procurement difficulties. The project has raised roughly $18 billion in loans with about $3 billion of Blue Owl equity, and Blue Owl earns 9% during development rising to around 11% levered once complete. Blue Owl says the notice doesn't change its commitments. Elsewhere, Oppenheimer put Oracle among software vendors with AI businesses over $1 billion while noting buyers now want measurable returns; Oracle reported $11.6 billion of quarterly cloud revenue, up 62%, with cloud infrastructure more than doubling to $7.4 billion, but free cash flow of negative $5 billion. Oracle Financial Services also launched two AI products for financial crime investigation, Nexus Case Flow and Nexus Reach, at the ACAMS conference in Las Vegas. Two GuruFocus valuation pieces put GF Value at $193.13 against Monday's $132.60 close, a 31.3% discount, but tag it a possible value trap, and note insiders sold $119.1 million over twelve months with no buying. Three further Oracle headlines, all headline-only, point the other way on sentiment: Meta's enterprise AI push knocking Microsoft and Oracle, and oncology AI entering the EHR.
SpaceX, the biggest headline cluster
SPCX rose 2.7% and carries more items than anything else on the list, all headline-only. The recurring threads are Starship Flight 14, described as the first orbital flight with 26 Starlink V3 satellites deployed despite an engine failure, and a wave of analyst initiations and reiterations around it: TD Cowen starting at Buy with a $200 target and expecting AI compute leasing to become SpaceX's largest business by Q1 2027, CLSA initiating with a $250 target, Deutsche Bank maintaining $235, and BofA and Clear Street reiterating Buy. Separate headlines flag the engine failure's possible impact on NASA's moon objectives, NASA giving Boeing Starliner a $359 million lifeline, and VEON/Beeline launching Starlink satellite-to-mobile in Kazakhstan. Rocket Lab, down 3.6%, appears alongside a headline on Goldman flagging SpaceX in a growth screen and a Cathie Wood $64 million purchase across two stocks.
Apple weak, Netflix upgraded
AAPL fell 2.7% with a large but thin set of headlines: Morgan Stanley reiterating a $360 target, several pieces framing Meta's AI Muse and local desktop AI as a competitive threat, BofA flagging a new AI risk, and reports that new CEO John Ternus is reworking product development and launch strategy. Much of the rest is routine ETF flow reporting. NFLX gained 1.5% on a Deutsche Bank upgrade to Buy from Hold, with the target cut to $95 from $100, the stated reasoning being global scale, an international production advantage and valuation at roughly 18x estimated earnings. Netflix also picked up exclusive WWE streaming rights in Japan from 1 October.
The smaller movers
AXSM fell 3.9%, with headlines on heavy put skew in options ahead of a binary catalyst and a Deutsche Bank target cut to $267. GNRC rose 3.4% despite a Jefferies target cut on execution concerns. TMC fell 3.1% as it added ExxonMobil veteran Liam Mallon to its board ahead of a seabed mining push, confirmed by an 8-K. NTAP gained 2.4% amid a heavy product news day, a Novus storage architecture for AI workloads, AI data engine updates, a Supermicro partnership and a European data sovereignty service, alongside a note that CEO George Kurian sold 37,000 shares. SIBN rose 2.0% on FDA clearance of its iFuse Granite Onyx system. Smaller items: TEVA up 2.4% on FDA approval of the Degevma biosimilar, JOBY down 2.4% with a $45 million contract ceiling increase for an autonomous cargo project, SRFM down 1.7% naming Jason Secore CFO, RVMD up 1.4% with a Brookline Capital Buy initiation and an officer selling $743k, and BFLY down 0.6% on an Evercore ISI Outperform initiation.
Quiet names
The rest of the list is largely routine. AVGO, TSM, SNDK, VRT, CRDO, MPC, COST, APH, WULF, NVTS, AFL, AU, KGS, ALAB and PGY all moved 2% or less, and their items are ETF flow tallies, GF Value screens and single-line analyst notes with nothing new behind them.
BYSI doubles on volume, then gives it back pre-market
BeyondSpring was the biggest mover on the list, up 44.1% to $1.12 on Monday's close, on volume of 3.49 million shares against an 820,000-share average. The Yahoo quote page read in full gives no reason for the move, but there's an 8-K on the list the same day, headline-only, flagging Item 1.01 entry into a material definitive agreement plus an Item 8.01 other-events disclosure, which is the obvious place to look. Worth knowing the context: the company is a clinical-stage oncology name with a $46 million market cap, $6.53 million of cash, 44 employees, and a five-year return of -92.6%, and even after Monday it is down 31% year to date. The same page shows a pre-market print of $0.8241, down 26.4%, so a good chunk of the pop was already unwinding.
AMC at a 52-week high on a repaired balance sheet
AMC was up 11.9% and printed a 52-week high of $3.19, which Investing.com puts at a 210% gain over six months against a 1-year change of just 5.83%. The article ties the run to real operating news rather than sentiment alone: record Q2 2026 revenue and EBITDA, revenue up 14.2% and adjusted EBITDA up about 37% year on year, helped by the Spider-Man: Brand New Day opening at $355 million domestic and $927 million global. Alongside that, AMC has put through a $3.97 billion refinancing, including $2 billion of first-lien notes and an $850 million first-lien term loan, which drove a Moody's upgrade of the corporate family rating to B3 from Caa2 and liquidity to SGL-3 from SGL-4, plus an S&P upgrade to B- from CCC+ citing better operating performance and a path to sustained positive free cash flow. Shareholders also approved raising the 2024 equity incentive plan pool from 25 million to 50 million shares. Investing.com notes the price is above its own InvestingPro fair value of $2.93. Separately, a TradingView post flags a daily double-bottom breakout with support cited at $2.70 to $2.80.
Credo down on fresh insider selling
Credo fell 8.7% to $192.67. Investing.com attributes it specifically to a newly disclosed Form 4 covering insider selling on September 26 by the co-founder and CTO through the Cheng Huang Family Trust, the latest in a run of such filings, landing while the stock is still recovering from an 18-20% single-session drop after Q1 fiscal 2027 results in early September. Mizuho cut its target to $245 from $290 on September 21 and JPMorgan went to $310 from $335 on September 2, both maintaining positive ratings. The piece also points to a weak tech tape that day and the stock's high multiple. GuruFocus, covering the same decline, puts insider sales at $449.8 million over twelve months with no purchases, a GF Score of 85 with momentum 10/10 and profitability 4/10, and a trailing P/E of 68.8x against a five-year median of 131.8x. The Yahoo page shows the 52-week range at $86.49 to $308.67 and a 1-year target estimate of $280.10.
Surf Air on a CFO hire and an FAA agreement
Surf Air was up 7.2% on two separate pieces of company news. It named Jason Secore CFO effective September 30, an 18-year aviation and technology finance veteran who was previously CFO at Matternet, where he ran the move from venture-backed to publicly traded. Earlier the same day it disclosed a Memorandum of Agreement with the FAA making it a Participating Airspace User in the SMART initiative, contributing network planning, flight performance engineering, dispatch and flight operations specialists to the agency's airspace modernisation lab. Both GuruFocus pieces frame the fundamentals as thin: market cap around $137 to $147 million, GF Score 51 with growth 9/10 but financial strength 2/10, trailing EPS of -1.7, a Piotroski F-Score of 2 and an Altman Z-Score of -10.54, no insider buying and roughly $0.25 million of insider selling over twelve months. There's also an 8-K on the list, headline-only, under Item 5.02 officer changes, which lines up with the CFO announcement.
AngloGold hit by the macro tape, not company news
AngloGold Ashanti fell 6.3% to $92.77, and four items cover it. Investing.com puts the move down to a risk-off wave: Brent above $108 after President Trump rejected Iranian ceasefire terms, the US 10-year trading above 5.2%, and the S&P, Dow and Nasdaq all lower, which raises the opportunity cost of holding gold-linked equities. Two stock-specific items add to it, a BMO downgrade from Outperform to Market Perform, and a recent quarter where both EPS and revenue came in below consensus. The stock also crossed below its 200-day moving average of $96.58, trading as low as $91.85, against a 52-week range of $62.55 to $129.14, and GuruFocus calls it 41.2% above its $65.69 GF Value despite a GF Score of 82 and a trailing P/E of 12.4x versus a 21.6x five-year median. The fourth item is a Mining Forum Americas transcript, which is filed under AU on the list but is actually AAUC, Anglo Gold Ashanti's separately quoted line, so read it with that in mind: output rising from 379,000 ounces last year to 600,000 to 650,000 next year and near 800,000 by 2030, Kurmuk in Ethiopia weeks from first pour and a few weeks behind schedule but on budget at a projected $1,300 per ounce AISC on a 20-year power deal at $0.04 per kilowatt hour, Sadiola heading below $1,700, Côte d'Ivoire at $1,800 to $1,900, pro forma cash of CAD 487 million and a cash distribution policy promised before year-end.
TeraWulf slips with puts stacking up
TeraWulf was down 3.9% to $15.12, and is off 13.3% over the past week. The options coverage is the useful part: the put/call ratio ran at 1.44 against an average of 0.38, and 30-day implied volatility rose 2.3 points to 78.08, which the writer reads as traders buying downside protection. On fundamentals, GuruFocus flags a GF Score of 43, financial strength and profitability both 2/10, momentum 8/10, a P/S of 39.79 against a 12.45 three-year median, debt-to-equity of 35.56, an Altman Z-Score of -0.64, and a GF Value of $5.74 versus the market price. Insiders sold $36.1 million over twelve months against $0.4 million bought.
Navitas wins an Army contract after the close
Navitas closed down 3.9%, but the news on the list is dated the following morning and points the other way. The Army selected it for the ALATTIS program to develop 10 kV silicon carbide power semiconductors, extending its GeneSiC range above the 6.5 kV devices it makes today, and building a domestic manufacturing process for ultra-high-voltage SiC that the article says does not currently exist in the US. The award value was not disclosed. The prototype work covers design, fabrication and testing of 10 kV IGBTs and PiN diodes, sponsored by the Army Research Laboratory under Combat Capabilities Development Command, built on the company's trench-assisted planar architecture. GuruFocus notes the stock rose 10.74% in pre-market on it, and several headline-only items on the list, one citing a 20% move, describe the same surge. So the -3.9% on your quote is stale relative to this.
SpaceX Starship cluster
SPCX was down 2.2% and carries by far the most headlines, all headline-only, and they all circle one event: Starship's 14th flight reached orbit for the first time and deployed 26 Starlink V3 satellites, with one headline noting the engine issue and another saying shares were up 1.1% on the news. Around that sit a string of analyst actions, TD Cowen initiating at Buy citing AI compute and Starlink, CLSA initiating with a $250 target, Deutsche Bank maintaining $235, and reiterations from BofA, Bernstein, Clear Street and Evercore. None of these were read in full, so take them as stated and no more.
Oracle headlines, all unread
Oracle was down 3.3% with a dozen headline-only items and no full text. The ones with actual claims behind them: Meta unveiling an enterprise AI push aimed at Salesforce and ServiceNow, with Microsoft and Oracle stocks said to have fallen on it; an $18 billion Oracle AI project hitting a hurdle; Larry Ellison pledging $9.2 billion of stock against loans; Michael Burry adding 2027 put bets naming Oracle and Nebius; a new financial-crime AI toolset; and a Form 4. Two valuation headlines point in opposite directions, one calling it undervalued on GF Value after the drop, another putting DCF value at $113.
Everything else was quiet or headline-only
The rest of the list is small moves with single-line news. SanDisk fell 3.7% with four technical and one "600% rally heading into a big memory test" headline, none read. Astera Labs -3.6% and Vertiv -3.6% appear only via ETF outflow notes and a Bernstein reiteration. Joby -3.3% has a $45 million contract ceiling increase for an autonomous cargo project. Netflix -2.7% carries a Deutsche Bank upgrade with the target lowered to $95, and Butterfly Network -2.6% an Evercore initiation at Outperform. On the upside, VerifyMe +3.1% has a Form 4 and an 8-K, SI-Bone +0.9% got FDA clearance for its iFuse Granite Onyx system, Incyte +0.8% had target raises from JP Morgan to $123 and HC Wainwright to $152, and Vicor +1.1% is noted as up 44.9% across September. Iovance was flat but raised its 2026 revenue forecast above estimates, and Costco was flat with Deutsche Bank trimming to $1,079 and Argus holding $1,230. Apple's twenty-odd entries are almost entirely daily ETF flow reports and carry no news.
BYSI up 44% with no story attached
BeyondSpring is the biggest mover on the list, up 44.1%. The only item behind it is a Yahoo Finance chart alert flagging a 13.9% move at 1.7 times its own 20-day ATR on volume 3.6 times the 20-day average, and the page itself returned nothing but a German cookie consent notice. So there is a large move and a volume spike on record, and no stated reason anywhere in the material. This is the one worth looking at directly.
AMC at a 52-week high
AMC is up 11.7% and Investing.com carried the same 52-week-high piece twice, at $3.19, which it puts at a 210% gain over six months against a 1-year change of just 5.83%. The article notes the price sits above InvestingPro's fair value of $2.93. The background it gives is genuinely substantial: record Q2 2026 revenue, up 14.2%, with adjusted EBITDA up roughly 37% year on year, helped by a record weekend off the opening of Spider-Man: Brand New Day, which took $355 million domestically and $927 million worldwide. AMC has also put out a $3.97 billion refinancing including $2 billion of first-lien notes and an $850 million first-lien term loan. Moody's lifted the Corporate Family Rating to B3 from Caa2 and liquidity to SGL-3 from SGL-4, and S&P moved it to B- from CCC+ citing better operating performance and a path to sustained positive free cash flow. Shareholders also approved raising the 2024 equity incentive plan pool from 25 million shares to 50 million.
Credo down on insider selling
Credo is down 8.7%, and there is a lot of material on it. Investing.com's explainer says the fall followed a newly disclosed Form 4 covering insider sales on September 26 by the co-founder and CTO through the Cheng Huang Family Trust, the latest in a run of such filings. Two more Form 4 headlines, for September 26 and 27, are in the list separately. The stock traded down to $196.94 intraday from a $205.70 open. Context given: an 18-20% single-session drop after Q1 fiscal 2027 results in early September, Mizuho cutting its target to $245 from $290 on September 21, JPMorgan to $310 from $335 on September 2, and a peak near $308 in June, all against a weak tech tape that day. Set against that, a GuruFocus piece from September 25, written after a 7.7% gain to $210.97, put GF Value at $265.43, a P/E of 75.3x versus a five-year median of 143.5x, and a GF Score of 85, while also recording $444.5 million of insider selling over twelve months with no buying. A separate Yahoo chart alert flags the drop at 1.5 times ATR20 but on volume only 0.3 times the 20-day average, which is worth noting given how heavy the news flow is.
Surf Air joins FAA airspace programme
Surf Air Mobility is up 6.8% after announcing a Memorandum of Agreement with the FAA on September 28 to take part in the SMART initiative, which makes it a Participating Airspace User contributing network planning, flight performance engineering, dispatch and flight operations staff to the agency's SMART Innovation Lab work on scheduling and trajectory models. GuruFocus adds the financial frame: market cap $137 million, P/S of 0.66 against a 0.46 historical median, GF Score 51 with growth at 9 out of 10 but financial strength at 2 and profitability at 3, no meaningful P/E because the company is loss-making, and roughly $249,000 of insider selling with no buying over twelve months.
AngloGold hit by yields and oil
AngloGold Ashanti is down 6.3%. The Investing.com piece attributes the fall, 7.3% pre-open to $91.81 from a $99.03 prior close, to a risk-off wave driven by Brent climbing above $108 after Trump rejected Iran's ceasefire terms and the US 10-year trading above 5.2%, which raises the opportunity cost of holding gold-linked equities. Company-specific pressure came from a BMO Capital downgrade to Market Perform from Outperform and a recent quarter where both EPS and revenue missed consensus. Gold futures on the same page were down 3.86% and silver down 5.53%, so this is sector-wide rather than AngloGold alone.
Wells Fargo starts Forgent at Equal-Weight
Forgent Power Solutions is down 6.1%. Wells Fargo initiated coverage at Equal-Weight on September 25 with the stock at $38.96, which follows a +21.03% month. The September 15 quarter beat: EPS of 0.25 against 0.2421 expected, revenue of $461.7 million against $434.2 million. Consensus target mean stood at $61.54, and the analyst split is 14 ratings, six strong buy, six buy, two hold, unchanged from a month earlier. Oppenheimer reiterated Outperform and TD Cowen maintained Buy on September 16.
TeraWulf and Navitas on valuation notes
TeraWulf is down 3.9%, with two GuruFocus pieces. Today's covers options activity: a put/call ratio of 1.44 against a 0.38 average and 30-day implied volatility up 2.3 points to 78.08, with the stock off 25 cents to about $15.49. The valuation piece from September 25 has it at $15.74, P/S of 39.79 against a 12.45 median, GF Score 43, and GF Value of around $5.74 versus the market price, with insiders selling $36.1 million against $0.4 million bought over twelve months. Navitas is also down 3.9%, and the GuruFocus note on it is from September 25 when it rose 3.0% to $12.20, flagging GF Value at $2.96, a 52-week range of $6.22 to $34.17, GF Score 63 with financial strength at 8 but valuation at 1, and $150.7 million of insider selling with no buying.
Planet Labs and a Planet Fitness mix-up
The PL line is down 3.7%, and the items filed under it cover two different companies. The Planet Labs piece on TradingView is the relevant one: record quarterly revenue of $116.1 million in early September, up 58% year on year, with FY2027 revenue guidance raised but fiscal Q3 guidance coming in below the Q2 revenue level. Shares fell about 50% over six months while the S&P rose 17.5%. The author counted 14 drops of 20% or more within 30 trading days since 2021, twelve with a full year of follow-on data, of which only four were higher a year later, median outcome a 25% loss, range from -56% to +576%. TTM revenue is up 44%, net loss has widened to 95% of revenue from 72% three years ago, but operating cash flow is positive at 31% of revenue, and Tanager-2 has shipped to its launch site. The other two items under the same ticker are about Planet Fitness: a Lord Abbett Developing Growth Fund Q3 letter naming it a detractor on consumer discretionary security selection, and a GuruFocus note with the stock at $42.68, down 60.6% year to date, GF Value $107.15, P/E 14.5x against a 46.3x five-year median, and net insider buying of $0.7 million.
SanDisk chart chatter only
SanDisk is down 3.7%, and there is nothing of substance behind it. The two full-text items are the same TradingView post, an admittedly casual trendline observation the author says he won't trade. The other two are headline-only, one on $1,700 breaking with expanding downside risk and one framing the 600% rally as heading into a memory test. No news.
Oracle headline cluster
Oracle is down 3.3% with the heaviest headline flow of the day, all unread. The recurring threads: Meta unveiling an enterprise AI push aimed at Salesforce and ServiceNow, with Microsoft and Oracle stocks named as falling on it; Larry Ellison pledging a further $9.2 billion of Oracle stock as loan collateral, mentioned in several headlines alongside the Warner Bros. Discovery deal; ShinyHunters expanding attacks on Oracle's PeopleSoft per Google; a DCF piece putting intrinsic value at $113; oncology AI entering the EHR; and Form 4 and 144 filings for September 26, 27 and 28. Michael Burry also appears in a headline on the AI boom alongside Oracle and Nebius.
SpaceX flow after Starship's orbital flight
SPCX is down 2.2% despite by far the largest headline count in the list, none read in full. The event is Starship Flight 14 reaching orbit for the first time and deploying 26 Starlink V3 satellites, reportedly despite an engine failure. Around it: CLSA initiated at Accumulate with a $250 target, Deutsche Bank reiterated at $235, Clear Street reiterated buy after the milestone, Bernstein reiterated on the Starlink growth outlook, Evercore has a $230 target tied to AI data centre and Colossus expansion, and Goldman flagged the name in a Russell 1000 revenue-growth screen. A Nasdaq CFO quote notes $86 billion of the $111 billion raised in the half came from SpaceX. Rocket Lab appears separately in a Cathie Wood buying headline.
Smaller names and analyst notes
Astera Labs is down 3.6% with headline-only items on a SOXX outflow, a Lord Abbett letter mention, a September 27 Form 4, and an older piece on a 21% surge. Vertiv, also down 3.6%, has a Bernstein reiteration on product quality checks and a GuruFocus overvaluation note with a GF Score of 87. Joby, down 3.4%, has a Form 4 and a chief policy officer selling $38,976 of stock. Netflix is down 2.7% with headlines on shares near two-year lows and a DCF at $77. On the analyst side: Brookline initiated Revolution Medicines at Buy, JP Morgan raised Incyte to $123 and HC Wainwright to $152, Jefferies cut Xenon's target on a trial pause and reiterated Hold on Avery Dennison at $181, Citizens reaffirmed CRISPR at $80, Deutsche Bank lowered Costco to $1,079 while Argus held at $1,230, and Jones Trading initiated Canaan at Buy. Ur-Energy had insider buying, VP Finance Jade Walle purchasing 96,556 shares.
Quiet names
Apple, Broadcom, TSMC, Costco and Amphenol all moved less than 1% and their many items are headline-only, mostly ETF flow tallies and DCF valuation notes. The one recurring Apple item with a hard number is the $5.7 billion jury verdict in the haptic/Taptic Engine patent case, which also appears as the reason Burford Capital shares gained. Celularity, up 1.4%, filed an 8-K covering a material agreement, a new financial obligation, unregistered equity sales and an officer change. Vicor is up 1.1% on a note about a 44.88% September gain, and NetApp, up 1.6%, is IBD's stock of the day.
TradingView
Trading 212
